Advertisement

Archives of Virology

, Volume 158, Issue 9, pp 1907–1915 | Cite as

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin

  • M. Sede
  • N. Laufer
  • D. Ojeda
  • A. Gun
  • P. Cahn
  • J. QuarleriEmail author
Original Article

Abstract

Even though new drugs have been approved for treatment of hepatitis C virus (HCV) infection, the risk of drug-drug interactions and concern about overlapping toxicities has hindered the development of studies in HIV/HCV-coinfected individuals. Traditional treatment with pegylated interferon plus ribavirin (peg-IFN + RBV) is very expensive and has a low rate of sustained virological response in coinfected patients, especially if they are infected with HCV genotype 1. Nitazoxanide (NTZ) is a drug that is being evaluated for the treatment of chronic HCV infection, both in HCV-monoinfected and HIV/HCV-coinfected patients. Understanding the NTZ resistance mechanism could allow the development of resistance to be minimized and would expand the treatment options, mainly in special populations such as HIV/HCV-coinfected patients. Similarly to IFN, NTZ increases the activity of the cellular protein kinase activated by double-stranded RNA (PKR), a key kinase in the innate antiviral response. In order to elucidate whether sequence heterogeneity in the PKR-binding domain of HCV NS5A genotype 1 could influence the antiviral activity of either NTZ monotherapy or peg-IFN + RBV, baseline and end-of-therapy plasma samples from two groups of eleven non-responder HIV/HCV-coinfected patients that had received NTZ or peg-IFN + RBV were studied. Most of the HCV NS5A sequences examined at the end of therapy did not change from the baseline, even after 30 days course of antiviral therapy. An extensive comparison of HCV NS5A genotype 1 and 4 sequences from the database with reported IFN therapy outcome was performed in order to infer their phylogenetic relationships. The HCV genotype 1 NS5A nucleotide sequences from therapy-non-responder patients were intermingled amongst those from the database, irrespective of their IFN-therapy outcome. When comparing NS5A-PKRBD amino acid sequences, significant differences were observed in genotype 4, but not in genotype 1 (p < 0.0001 and p > 0.05, respectively). In conclusion, despite IFN and NTZ sharing the protein kinase activated by double-stranded RNA as their cellular target, the HCV genotype 1 strategy to counteract the IFN action mediated by NS5A ISDR/PKRBD does not explain drug resistance in HIV/HCV-coinfected patients. Other viral factors that are possibly involved are discussed as well.

Keywords

Sustained Virological Response Nitazoxanide NS5A Sequence Sustained Virological Responder NS5A Amino Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This study was supported partially by grants from the University of Buenos Aires (SECYT-UBA 2012-2015), and the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET-PIP112 200801 01773).

Disclosure

The authors have no conflict(s) of interest.

References

  1. 1.
    Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453–463PubMedCrossRefGoogle Scholar
  2. 2.
    Medrano J, Resino S, Vispo E, Madejon A, Labarga P et al (2011) Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 18:325–330PubMedCrossRefGoogle Scholar
  3. 3.
    Rallon NI, Pineda JA, Soriano V, Neukam K, Vispo E et al (2012) Differences in virological response to peginterferon-alpha plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. J Acquir Immune Defic Syndr 60:117–123PubMedCrossRefGoogle Scholar
  4. 4.
    Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM et al (2008) Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 47:407–417PubMedCrossRefGoogle Scholar
  5. 5.
    Nissen NN, Barin B, Stock PG (2012) Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol 24:517–521PubMedCrossRefGoogle Scholar
  6. 6.
    Liu-Young G, Kozal MJ (2008) Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 22:449–457PubMedCrossRefGoogle Scholar
  7. 7.
    Kronenberger B, Zeuzem S (2012) New developments in HCV therapy. J Viral Hepat 19(Suppl 1):48–51PubMedCrossRefGoogle Scholar
  8. 8.
    Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F et al (2007) The way forward in HCV treatment–finding the right path. Nat Rev Drug Discov 6:991–1000PubMedCrossRefGoogle Scholar
  9. 9.
    Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J et al (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28–38PubMedCrossRefGoogle Scholar
  10. 10.
    Romano KP, Ali A, Aydin C, Soumana D, Ozen A et al (2012) The molecular basis of drug resistance against Hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 8:e1002832PubMedCrossRefGoogle Scholar
  11. 11.
    Strahotin CS, Babich M (2012) Hepatitis C variability, patterns of resistance, and impact on therapy. Adv Virol 2012:267483PubMedGoogle Scholar
  12. 12.
    Taylor LE, Swan T, Mayer KH (2012) HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 55(Suppl 1):S33–S42PubMedCrossRefGoogle Scholar
  13. 13.
    He Y, Duan W, Tan SL (2007) Emerging host cell targets for hepatitis C therapy. Drug Discov Today 12:209–217PubMedCrossRefGoogle Scholar
  14. 14.
    Tan SL, Ganji G, Paeper B, Proll S, Katze MG (2007) Systems biology and the host response to viral infection. Nat Biotechnol 25:1383–1389PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson VR, Curran MP (2007) Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67:1947–1967PubMedCrossRefGoogle Scholar
  16. 16.
    Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS (2008) Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 52:4069–4071PubMedCrossRefGoogle Scholar
  17. 17.
    Yon C, Viswanathan P, Rossignol JF, Korba B (2011) Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells. Antiviral Res 91:233–240PubMedCrossRefGoogle Scholar
  18. 18.
    Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA et al (2009) The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 137:1827–1835PubMedCrossRefGoogle Scholar
  19. 19.
    Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M et al (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18:5208–5218PubMedGoogle Scholar
  20. 20.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T et al (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77–81PubMedCrossRefGoogle Scholar
  21. 21.
    Gale MJ Jr, Korth MJ, Katze MG (1998) Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10:157–162PubMedCrossRefGoogle Scholar
  22. 22.
    Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U et al (2004) Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53:1345–1351PubMedCrossRefGoogle Scholar
  23. 23.
    Chen TM, Huang PT, Wen CF, Tung JN, Chow KC et al (2011) Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. J Viral Hepat 18:119–128PubMedCrossRefGoogle Scholar
  24. 24.
    Laufer N, Abusamra L, Bolcic F, Gun A, Rolon MJ et al (2011) No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30 days course of nitazoxanide monotherapy. Antiviral Res 92:497–499PubMedCrossRefGoogle Scholar
  25. 25.
    Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM et al (2012) Analysis of functional differences between Hepatitis C virus NS5A of genotypes 1–7 in infectious cell culture systems. PLoS Pathog 8:e1002696PubMedCrossRefGoogle Scholar
  26. 26.
    Katoh K, Kuma K, Toh H, Miyata T (2005) MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res 33:511–518PubMedCrossRefGoogle Scholar
  27. 27.
    Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY et al (2008) The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 49:899–907PubMedCrossRefGoogle Scholar
  28. 28.
    Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB (2008) Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28:574–580PubMedCrossRefGoogle Scholar
  29. 29.
    Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME (2012) The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 32(Suppl 1):146–150PubMedCrossRefGoogle Scholar
  30. 30.
    El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L et al (2012) NS5A sequence heterogeneity of Hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 50:3886–3892PubMedCrossRefGoogle Scholar
  31. 31.
    Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series, pp 91–98Google Scholar
  32. 32.
    Posada D, Crandall KA (1998) MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817–818PubMedCrossRefGoogle Scholar
  33. 33.
    Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52:696–704PubMedCrossRefGoogle Scholar
  34. 34.
    Huson DH, Richter DC, Rausch C, Dezulian T, Franz M et al (2007) Dendroscope: an interactive viewer for large phylogenetic trees. BMC Bioinforma 8:460CrossRefGoogle Scholar
  35. 35.
    Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R et al (2012) Longitudinal analysis of the 5′UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Res 95:72–81PubMedCrossRefGoogle Scholar
  36. 36.
    Bolcic F, Sede M, Moretti F, Westergaard G, Vazquez M et al (2012) Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Arch Virol 157:703–711PubMedCrossRefGoogle Scholar
  37. 37.
    Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM (2010) Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat 17:208–216PubMedCrossRefGoogle Scholar
  38. 38.
    Boulestin A, Sandres-Saune K, Payen JL, Rostaing L, Pasquier C et al (2003) Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha. J Infect Dis 188:1367–1370PubMedCrossRefGoogle Scholar
  39. 39.
    Dal Pero F, Tang KH, Gerotto M, Bortoletto G, Paulon E et al (2007) Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. J Infect Dis 196:998–1005PubMedCrossRefGoogle Scholar
  40. 40.
    Gale M Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436:939–945PubMedCrossRefGoogle Scholar
  41. 41.
    Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H et al (2006) Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 13:582–590PubMedCrossRefGoogle Scholar
  42. 42.
    Macdonald A, Harris M (2004) Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485–2502PubMedCrossRefGoogle Scholar
  43. 43.
    Podevin P, Sabile A, Gajardo R, Delhem N, Abadie A et al (2001) Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology 33:1503–1511PubMedCrossRefGoogle Scholar
  44. 44.
    Murphy MD, Rosen HR, Marousek GI, Chou S (2002) Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 47:1195–1205PubMedCrossRefGoogle Scholar
  45. 45.
    Yahoo N, Sabahi F, Shahzamani K, Malboobi MA, Jabbari H et al (2011) Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment. J Med Virol 83:1332–1337PubMedCrossRefGoogle Scholar
  46. 46.
    Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R et al (2012) Longitudinal analysis of the 5′UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Res 95:72–81PubMedCrossRefGoogle Scholar
  47. 47.
    Mederacke I, Wedemeyer H (2009) Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? Ann Hepatol 8:166–168PubMedGoogle Scholar
  48. 48.
    El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L et al (2012) NS5A sequence heterogeneity of Hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon/ribavirin therapy in Egyptian patients. J Clin Microbiol 50:3886–3892PubMedCrossRefGoogle Scholar
  49. 49.
    Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S et al (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 30:1259–1269PubMedCrossRefGoogle Scholar
  50. 50.
    Chuang WL, Yu ML (2012) Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol 48:22–30PubMedCrossRefGoogle Scholar
  51. 51.
    Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL et al (2012) Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 17:477–484PubMedCrossRefGoogle Scholar
  52. 52.
    El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S et al (2012) Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One 7:e30513PubMedCrossRefGoogle Scholar
  53. 53.
    El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR et al (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38–47PubMedCrossRefGoogle Scholar
  54. 54.
    El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S et al (2012) Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology 55:1–11PubMedCrossRefGoogle Scholar
  55. 55.
    Yano Y, Seo Y, Miki A, Saito M, Kato H et al (2012) Mutations in non-structural 5A and rapid viral response to pegylated interferon-alpha-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Int J Mol Med 30:1048–1052PubMedGoogle Scholar
  56. 56.
    Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G et al (2001) Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75:6095–6106PubMedCrossRefGoogle Scholar
  57. 57.
    Kumthip K, Chusri P, Jilg N, Zhao L, Fusco DN et al (2012) Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 86:8581–8591PubMedCrossRefGoogle Scholar
  58. 58.
    Sanghvi VR, Steel LF (2011) The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR. J Virol 85:12614–12621PubMedCrossRefGoogle Scholar
  59. 59.
    Brand SR, Kobayashi R, Mathews MB (1997) The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. J Biol Chem 272:8388–8395PubMedCrossRefGoogle Scholar
  60. 60.
    Clerzius G, Gelinas JF, Gatignol A (2011) Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol 21:42–53PubMedCrossRefGoogle Scholar
  61. 61.
    Lee C (2011) Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy. Arch Pharm Res 34:1403–1407PubMedCrossRefGoogle Scholar
  62. 62.
    Osinusi AWC, Zhang X, Shivabesan G, Shivakumar B, Silk R, Doonquah L, Henn S, Teferi G, Masur H, Kottilil S, Fishbein D (2012) Augmentation of Interferon signaling pathway by Nitazoxanide: a therapeutic strategy for HIV/HCV Coinfected Relapsers to Peg-interferon and Ribavirin therapy. In: 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, USAGoogle Scholar
  63. 63.
    Amorosa VU, T, Johnson V, Kang M, Luetkemeyer A, Bardin M, Haas D, Chung R, Yesmin S, Coughlin K, Martinez A, Adams MB, Alston-Smith B, Tebas P, Peters M (2012) The addition of nitazoxanide to peginterferon alfa-2a and ribavirin does not significantly improve sustained virologic response in HCV treatment-naïve genotype 1 HIV-1/HCV co-infected subjects: results of ACTG 5269. XIX International AIDS Conference. Washington, USAGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • M. Sede
    • 1
    • 2
  • N. Laufer
    • 1
    • 2
    • 3
  • D. Ojeda
    • 1
    • 2
  • A. Gun
    • 4
  • P. Cahn
    • 3
    • 4
  • J. Quarleri
    • 1
    • 2
    Email author
  1. 1.Instituto de Investigaciones Biomédicas en Retrovirus y Sida, Facultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
  2. 2.CONICETBuenos AiresmArgentina
  3. 3.División InfectologíaHospital Juan Fernández, CABABuenos AiresArgentina
  4. 4.Fundación HuéspedBuenos AiresArgentina

Personalised recommendations